NCT02485301 - A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults | Biotech Hunter

Enrollment

3,024

Participants

Timeline

Start Date

July 15, 2015

Primary Completion Date

December 23, 2016

Study Completion Date

December 23, 2016

Conditions

Virus Diseases

Interventions

BIOLOGICAL

GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)

A single dose administrated intramuscular

DRUG

Placebo

A single dose administrated intramuscular

Trial Locations (5)

GSK Investigational Site, Bamenda

GSK Investigational Site, Yaoundé

GSK Investigational Site, Bamako

GSK Investigational Site, Abuja

GSK Investigational Site, Dakar